ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Time
3,013 announcements with these filters
Q2 FY27 revenue flat QoQ at ₹2,486 Mn, down 3.8% YoY; EBITDA margin 17.60%; PAT ₹321 Mn. AI-first pivot is pressuring near-term revenue.
Q2 FY27 standalone revenue ₹3,121 Mn (+52% YoY), EBITDA ₹396 Mn (12.7% margin), PAT ₹228 Mn (+77%). BTS defence/space drove growth; order book ₹19.5 Bn (+38%).
Q2FY27 revenue Rs 2,087 Cr (+32.9% reported, +34.7% LFL), EBITDA Rs 111 Cr at 5.3% margin, PAT Rs 61 Cr (+66%). Strategy: consolidate fragmented distribution and scale MedTech (IVD, cardio-ortho).
Q2 FY27 revenue ₹3,809L (+195% YoY), PAT ₹660L (17.3% margin). H1 FY27 revenue ₹7,238L, PAT ₹1,192L. Growth is acquisition-led, with Dubai entry.
H1 FY27 consolidated revenue rose about 39%, EBITDA about 40% and PAT 40%. Part of the revenue growth is metal pass-through. Management expects margins to dip as low-margin assembly scales, and its growth outlook is hedged.
Q2 FY27 consolidated revenue Rs 1,323 Cr (+28% YoY), EBITDA Rs 111 Cr (8% margin), PAT loss Rs 5 Cr. H1 PAT loss Rs 181 Cr. Speciality segments improving; commodity PVC and VAC still weak.
Q2 FY27 consolidated revenue INR 133.7 Cr, EBITDA INR 55 Cr (41% margin), PAT INR 24.8 Cr (19%). Pepperfry turnaround, Pepcart logistics, data-centre and AI platforms.
H1 FY27 revenue ₹83.46 Cr (+71.6%) and PAT ₹7.04 Cr (+126.3%) on government project execution. Margin sustainability and defence answers gave no numbers. The ₹170 Cr FY27 target is the only hard guide.
Q2 PAT ₹64.7 Cr (+54% YoY) includes a ₹15 Cr deferred tax write-back; PBT grew only 13%. Fee income (₹61.3 Cr TTM) roughly covers ₹63.4 Cr expenses, and carry is lumpy and realization-driven.
Revenue rose 18.4% but volume grew only 2.9%, so growth is mainly price-led. EBITDA margin fell about 100bps to 15.9% under input inflation, and management leans on adjusted metrics excluding PLI and Project Bold to present underlying performance.
Q2 FY27 consolidated revenue ₹16,882.76 lakh (+56.82% YoY), PAT ₹974.65 lakh (+2366% on a low base), EBITDA margin 13.98%. Strategy centres on solar, BESS and EV charging.
Revenue up 11% to ₹7,827 Cr, but EBITA margin fell to 25.1% from 31.3%; US down 13.4% QoQ on Tolvaptan erosion; management hedged FY28 outlook.
Q2/H1 FY27 deck with no P&L figures in the provided slides. Strategy centres on anode expansion from 20K to 44K MT and 500 MT graphene by Sep 2028.
Q2FY27 revenue Rs 3,450 cr (+49% YoY), PAT Rs 291 cr (+10%), EBITDA margin 18.2% (-329 bps). H1 revenue Rs 6,859 cr (+35%). Targets 2.2x revenue by FY30.
Record Q2: revenue ₹359 Cr (+47%), EBITDA ₹66 Cr (+54%). No revenue guidance given. Gross margin fell 1.1 pts, and inventory of ₹358 Cr is at a seasonal peak.
Standalone Q2 PAT more than tripled to ₹10.16 Cr on ₹46.64 Cr sales. Consolidated H1 PAT of ₹18.62 Cr trails standalone ₹20.19 Cr due to Beryl subsidiary losses. Management hedges on Beryl breakeven and acquisition plans.
Q2 FY27 standalone sales ₹1,722.5 Cr (+19% YoY), EBITDA ₹191.1 Cr (11.0% margin), PAT ₹115.2 Cr (-14%). Consolidated revenue ₹2,284 Cr (+17%), PAT ₹130.3 Cr (-18%). No numerical guidance.
Q2 FY27 operating income ₹1,054 Mn (+18.9% YoY), EBITDA ₹77 Mn at 7.3% margin, PAT loss ₹21 Mn. EU-GMP cost base weighs on margins.
Q2 revenue rose 64.4% YoY to ₹222.97 Cr and PAT 57.3% to ₹28.06 Cr, led by volume. Management deflected on equity dilution and the freeze-dried (FDC) start date, which slipped 1-2 months.
H1 revenue ₹84.06 Cr (+378% YoY from a small base), EBITDA margin 13.49%, PAT ₹8.18 Cr. Management hedged heavily ('hopefully', 'I think so') and gave no FY27 margin figure.
H1 FY27 revenue INR 839 Mn (+107% YoY), EBITDA INR 92 Mn (+19%), PAT INR 90 Mn (+27%), driven by Taggd acquisition. Margins compressed sharply.
Q2 FY27 revenue ₹584.7 Cr (+23.2%), record EBITDA margin 12.9%, PAT ₹29.0 Cr (+35.7%). H1 revenue ₹1,065.2 Cr (+30.8%). Growth led by retail and general trade.
H1FY27 revenue flat at ₹716.7 Cr; EBITDA ₹81.6 Cr at 11.4% margin; PAT ₹51.3 Cr, up 3%. Q2 weakened on weak monsoon and West Asia crisis; exports and branded formulations held up.
Record Q2 revenue ₹1,242 Cr (+18%), EBITA ₹233 Cr (18.8% margin), PAT ₹142 Cr. Growth is online-led. The NEET shortfall is unresolved, and the 30% FY27 guidance depends on an unquantified H2 recovery.
Q2FY27 revenue ₹10,263 Cr (+23.9% YoY), record EBITDA ₹2,156 Cr at 21.0% margin, PAT ₹1,124 Cr (+32.5% YoY). Lannett acquisition completed.
Q2 FY27 total revenue Rs13,630 Mn (+41.3% YoY), EBITDA Rs2,789 Mn (20.5% margin), PAT Rs757 Mn (+5.1% YoY). Expansion via 700+ beds planned.
Q2 FY27 consolidated revenue INR 26.3 Bn (+43.3% YoY), operating EBITDA INR 7.4 Bn (28.0% margin), PAT INR 4.6 Bn (+30.8% YoY). Cell capacity ramping; no explicit guidance given.
Q2 FY27 total income ₹2,906 Cr (-6.3% YoY); EBITDA ₹316 Cr at 10.9% margin; PAT ₹41 Cr (-60.9% YoY). Order book ₹43,837 Cr; H1 book-to-bill 3.95x.
Q2 FY27 revenue INR 13,197 Mn (+85% YoY), EBITDA INR 898 Mn (+95%), PAT INR 480 Mn (+62%). Capacity at 57,845 MT; Supa Phase 3 takes it to 72,200 MT by Q1 FY29.
Q2 FY27 revenue ₹1,143 mn (+28% YoY), EBITDA ₹407 mn (+21%), PAT ₹356 mn (-3%) on Gases volume ramp-up. Margins compressed by power and transport costs; BHEL ₹4,807 mn ASU order won.